Summary of Influenza Activity in New Mexico for Week Ending January 21, 2006:

- Nineteen of the 21 sentinel sites reported a total of 4,775 patient visits, of which 151 (3.18%) were positive for an influenza-like illness (ILI). The previous week ending January 21st reported 3.80% influenza-like illness.
- Sentinel clinical laboratories reported that 12.93% of influenza rapid antigen or immunofluorescence tests were positive for influenza A, and 0.92% was positive for Influenza B.
- NMDOH reported the state influenza activity as “REGIONAL” to the Centers for Disease Control and Prevention (CDC) (see table below for definitions).

Laboratory Activity in NM:

- For the week ending January 28, 2006, 16 of 17 sentinel clinical laboratories reported performing 433 rapid antigen or immunofluorescence (i.e., direct fluorescent antibody staining, DFA) tests, of which 56 (12.93%) were positive for influenza A, four (0.92%) were positive for influenza B and none were indistinguishable.
- Since October 2, 2005, 17 sentinel clinical laboratories have reported the results of 5,346 rapid influenza tests. One thousand and sixty-seven (19.95%) tests were positive, of which 1,034 detected influenza A, 28 detected influenza B, and 5 were indistinguishable.
- NMDOH Scientific Laboratory Division (SLD) has isolated influenza A in 67 of 186 (36%) specimens submitted since October 2005. Subtyping of the influenza A cultures has revealed 37 H3 and 1 H1 viral subtypes; N subtyping by CDC is pending.

Influenza-Related Pediatric Mortality

CDC reported one influenza-related pediatric death in Week 3. Since October 2, 2005, CDC has received reports of eleven influenza-related pediatric deaths, nine of which occurred during the current influenza season. There have been no reported deaths in NM.

Flu Activity in the Mountain Region and Texas

For the week ending January 21, 2006 (the most recent data available), influenza activity was reported as “Widespread” by Texas, Wyoming and Colorado; “Regional” by Idaho, Arizona and Utah, and “Local” by Montana and Nevada. Since October 2, 2005, laboratory testing from the National Respiratory and Enteric Virus Surveillance System (NREVSS) in the Mountain Region (NM, AZ, CO, UT, NV, ID, MT, WY) has identified 618 influenza A H3N2 isolates, 2 influenza A H1N1 isolates, 279 influenza A unknown subtype isolates, and 20 influenza B isolates.\(^3\)

---

\(^1\) Influenza-like Activity (ILI) is defined as Fever (≥ 100°F [37.8°C], oral or equivalent) AND cough and/or sore throat in absence of a KNOWN cause other than influenza.

\(^2\) Weekly ILI and lab data may change as additional reports are compiled.

\(^3\) Some rapid influenza tests cannot differentiate between types A and B.
National Flu Surveillance and Laboratory Activity

Nationwide, for the week ending January 21, 2006, 2.3% of patient visits to U.S. sentinel providers were due to influenza-like illness, which is above the national baseline of 2.2%. Influenza activity was reported as ‘Widespread’ by 5 states, ‘Regional’ by 23 states and New York City, ‘Local’ by 9 states and the District of Columbia, and ‘Sporadic’ by 13 states. One state reported ‘No Activity’. More information on national surveillance can be found at [http://www.cdc.gov/flu/weekly/](http://www.cdc.gov/flu/weekly/).

For the week ending January 21, 2006, 247 (10.8%) of 2,283 specimens tested for influenza viruses were positive by culture. Of these, 81 were influenza A (H3N2), 159 were influenza A that were not subtyped, and 7 were influenza B.

Antigenic characterization of 144 influenza viruses by CDC, since October 2005, has indicated the following:

- One hundred and twelve (85%) out of 132 H3N2 culture isolates are A/California/7/2004-like.
- The one subtyped H1 influenza A virus was antigenically similar to the vaccine strain A/New Caledonia/20/99.
- Seven (64%) of eleven influenza B viruses are B/Florida/07/2004-like; one is antigenically similar to the 2005-2006 vaccine strain B/Shanghai/361/2002; three strains belong to the B/Victoria lineage which is not contained in the 2005-06 vaccines.

Components of 2005-06 influenza vaccines:

- Fluvirin® (Chiron) contains A/California/7/2004-like (H3N2); and A/New Caledonia/20/99-like (H1N1); and B/Shanghai/361/2002-like strain.
- Both Fluzone® (sanofi) and Fluarix™ (GSK) contains A/New York/55/2004 (H3N2, an A/California/7/2004-like strain); and A/New Caledonia/20/99 (H1N1); and B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain).
- FluMist® (Medimmune, live attenuated vaccine) contains A/California/7/2004-like (H3N2); and A/New Caledonia/20/99 (H1N1); and B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain).

**Important message:**

On the basis of available antiviral testing results, CDC currently recommends that neither amantadine nor rimantadine be used for the treatment or prophylaxis of influenza A in the United States for the remainder of the 2005–06 influenza season. During this period, oseltamivir or zanamivir should be selected if an antiviral medication is used for the treatment and prophylaxis of influenza.

For more information, go to [www.health.state.nm.us/flu](http://www.health.state.nm.us/flu)
<table>
<thead>
<tr>
<th>Activity Level</th>
<th>ILI activity*/Outbreaks</th>
<th>Laboratory data</th>
</tr>
</thead>
<tbody>
<tr>
<td>No activity</td>
<td>Low</td>
<td>No lab confirmed cases†</td>
</tr>
<tr>
<td>Sporadic</td>
<td>Not increased</td>
<td>Isolated lab-confirmed cases</td>
</tr>
<tr>
<td></td>
<td>And</td>
<td>Lab confirmed outbreak in one institution‡</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>Recent (within the past 3 weeks) lab evidence of influenza in region with increased ILI</td>
</tr>
<tr>
<td>Local</td>
<td>Increased ILI in 1 region**; ILI activity in other regions is not increased</td>
<td>And</td>
</tr>
<tr>
<td></td>
<td>And</td>
<td>Recent (within the past 3 weeks) lab evidence of influenza in region with the outbreaks; virus activity is no greater than sporadic in other regions</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>Recent (within the past 3 weeks) lab confirmed influenza in the affected regions</td>
</tr>
<tr>
<td>Regional (doesn’t apply to states with ≤4 regions)</td>
<td>Increased ILI in ≥2 but less than half of the regions</td>
<td>And</td>
</tr>
<tr>
<td></td>
<td>Institutional outbreaks (ILI or lab confirmed) in ≥2 and less than half of the regions</td>
<td>Recent (within the past 3 weeks) lab confirmed influenza in the affected regions</td>
</tr>
<tr>
<td>Widespread</td>
<td>Increased ILI and/or institutional outbreaks (ILI or lab confirmed) in at least half of the regions</td>
<td>And</td>
</tr>
<tr>
<td></td>
<td>Recent (within the past 3 weeks) lab confirmed influenza in the state.</td>
<td></td>
</tr>
</tbody>
</table>

ILI activity can be assessed using a variety of data sources including sentinel providers, school/workplace absenteeism, and other syndromic surveillance systems that monitor influenza-like illness.

† Lab confirmed case = case confirmed by rapid diagnostic test, antigen detection, culture, or PCR. The sensitivity and specificity of these tests vary and the predicative value positive may be low outside the time of peak influenza activity. Therefore, a state may wish to obtain laboratory confirmation of influenza by testing methods other than point of care rapid tests for reporting the first laboratory confirmed case of influenza of the season. For assigning an influenza activity level, NMDOH Epidemiology and Response Division utilizes results of rapid influenza testing only after receiving evidence of at least one culture confirmed case.

‡ Institution includes nursing home, hospital, prison, school, etc.

**Region: population under surveillance in a defined geographical subdivision of a state. NMDOH Epidemiology and Response Division uses the five Public Health Regions for our state subdivisions.
Influenza Surveillance Graphs:

Percentage of Visits for Influenza-like Illness Reported by Sentinel Providers, NM and US, 2005-2006

Surveillance from 2004-05 Influenza Season

Percentage of Visits for Influenza-like Illness Reported by Sentinel Providers 2004 - 2005

*Morbidity and Mortality Weekly Report (published by the CDC)*